DR info

臨床試験数 : 21 / 薬物数 : 40 - (DrugBank : 11) / 標的遺伝子数 : 10 - 標的パスウェイ数 : 50

薬物ごとの開発者（Primary Sponsor）、臨床試験情報（抜粋）です。

Aliskiren
   Samsung Medical Center
      2010   Phase 3   NCT01715207   Korea, Republic of;
Aprovel
   Clinical Trials and Research Governance
      2013   Phase 2   EUCTR2010-023612-14-GB   United Kingdom;
   Royal Brompton and Harefield NHS Foundation Trust
      2010   Phase 3   EUCTR2010-019302-16-GB   United Kingdom;
Atenolol
   Brigham and Women's Hospital
      2007   Phase 3   NCT00723801   United States;
   Cardiff University
      2006   Phase 4   NCT01295047   United Kingdom;
      2005   Phase 4   EUCTR2005-000749-13-GB   United Kingdom;
   Forteza, Albert, M.D.
      2008   Phase 3   NCT01145612   Spain;
   New England Research Institutes
      2007   Phase 3   NCT00429364   Belgium;Canada;United States;
   Samsung Medical Center
      2010   Phase 3   NCT01715207   Korea, Republic of;
   University Hospital Gent
      2006   -   EUCTR2006-003991-37-BE   Belgium;
   University of British Columbia
      2008   Phase 2   NCT00593710   Canada;
BLOKIUM 50 mg comprimidos
   alberto forteza
      2008   -   EUCTR2007-001125-97-ES   Spain;
COZAAR INICIO 12,5 mg comprimidos recubiertos con pelicula
   alberto forteza
      2008   -   EUCTR2007-001125-97-ES   Spain;
Collection of samples of blood and urine
   University Hospital, Toulouse
      2022   -   NCT04970459   France;
Coozar
   University Hospital Ghent
      2009   -   EUCTR2007-005862-10-BE   Belgium;
Coversyl
   Cardiff University
      2005   Phase 4   EUCTR2005-000749-13-GB   United Kingdom;
Coversyl (perindopril)
   Bayside Health
      2004   Phase 3   NCT00485368   -
Cozaar
   University Hospital Ghent
      2009   -   EUCTR2007-005862-10-BE   Belgium;
Cozaar 50
   alberto forteza
      2008   -   EUCTR2007-001125-97-ES   Spain;
Doxycycline 100-200mg capsules daily for 6 months
   University of Oxford
      2013   Phase 2   NCT01949233   United Kingdom;
Doxycycline Hyclate Ph.Eur
   Clinical Trials and Research Governance
      2013   Phase 2   EUCTR2010-023612-14-GB   United Kingdom;
Irbesartan
   Clinical Trials and Research Governance
      2013   Phase 2   EUCTR2010-023612-14-GB   United Kingdom;
   Royal Brompton and Harefield NHS Foundation Trust
      2010   Phase 3   EUCTR2010-019302-16-GB   United Kingdom;
Irbesartan 150-300mg capsules daily for 6 months
   University of Oxford
      2013   Phase 2   NCT01949233   United Kingdom;
LOBIVON*28CPR
   OSPEDALE POLICLINICO S. MATTEO
      2008   Phase 3   EUCTR2008-001462-81-IT   Italy;
LORTAAN*28CPR RIV DIV
   OSPEDALE POLICLINICO S. MATTEO
      2008   Phase 3   EUCTR2008-001462-81-IT   Italy;
LOSARTAN POTASSIUM
   alberto forteza
      2008   -   EUCTR2007-001125-97-ES   Spain;
Losartan
   Assistance Publique - Hôpitaux de Paris
      2008   Phase 3   NCT00763893   France;
   Brigham and Women's Hospital
      2007   Phase 3   NCT00723801   United States;
   Forteza, Albert, M.D.
      2008   Phase 3   NCT01145612   Spain;
   OSPEDALE POLICLINICO S. MATTEO
      2008   Phase 3   EUCTR2008-001462-81-IT   Italy;
   University Hospital, Ghent
      2009   Phase 3   NCT00782327   Belgium;
   University of British Columbia
      2008   Phase 2   NCT00593710   Canada;
Losartan Potassium
   New England Research Institutes
      2007   Phase 3   NCT00429364   Belgium;Canada;United States;
Losartan and Atenolol or Propranolol
   National Taiwan University Hospital
      2007   Phase 2   NCT00651235   Taiwan;
Losartan and nebivolol
   IRCCS Policlinico S. Matteo
      2008   Phase 3   NCT00683124   Italy;
Losartan potassium
   University Hospital Gent
      2006   -   EUCTR2006-003991-37-BE   Belgium;
   University Hospital Ghent
      2009   -   EUCTR2007-005862-10-BE   Belgium;
Nebivolol
   OSPEDALE POLICLINICO S. MATTEO
      2008   Phase 3   EUCTR2008-001462-81-IT   Italy;
Perindopril
   Cardiff University
      2006   Phase 4   NCT01295047   United Kingdom;
Verapamil SR
   Cardiff University
      2005   Phase 4   EUCTR2005-000749-13-GB   United Kingdom;
Vibrox 100mg Capsules
   Clinical Trials and Research Governance
      2013   Phase 2   EUCTR2010-023612-14-GB   United Kingdom;